

Special Issue

Emerging Viral Pathogens and Vaccine Access for Vulnerable Populations

Message from the Guest Editor

Newly emerging viral pathogens such as the SARS-COV-2 virus that causes COVID-19 and the most recent Orthopox virus that causes Monkeypox have led to global infections that can be life-threatening, particularly in medically underserved and vulnerable individuals with underlying comorbidities. Approved vaccines are now available for some of these emerging pathogens; however, vaccine hesitancy and resistance have been particularly high among ethnic populations and rural communities due to a history and legacy of racial injustices, social inequities, and negative experiences within a long-standing, culturally insensitive healthcare system. Communities with poor vaccination rates are especially vulnerable, and continual community spread of the emerging pathogen can result in genetic changes that can allow these viral pathogens to be more contagious, cause more severe disease, and evade immune response produced by vaccinations. Therefore, it is essential to provide all communities with education, awareness, and access to safe and effective vaccines.

Guest Editor

Dr. Donald J. Alcendor

Center for AIDS Health Disparities Research, Department of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, TN 37208, USA

Deadline for manuscript submissions

closed (31 August 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/136470

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).